Qs Investors Has Cut By $3.88 Million Its Clorox Co Del (CLX) Holding; ZELDA THERAPEUTICS LTD ORD AUSTR (ZLDAF) Shorts Decreased By 74.6%

January 13, 2018 - By Nellie Frank

ZELDA THERAPEUTICS LTD ORD AUSTR (OTCMKTS:ZLDAF) had a decrease of 74.6% in short interest. ZLDAF’s SI was 12,700 shares in January as released by FINRA. Its down 74.6% from 50,000 shares previously. With 73,500 avg volume, 0 days are for ZELDA THERAPEUTICS LTD ORD AUSTR (OTCMKTS:ZLDAF)’s short sellers to cover ZLDAF’s short positions. The stock increased 6.59% or $0.006 during the last trading session, reaching $0.097. About 488,467 shares traded or 137.18% up from the average. Zelda Therapeutics Limited (OTCMKTS:ZLDAF) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Qs Investors Llc decreased Clorox Co Del (CLX) stake by 39.62% reported in 2017Q3 SEC filing. Qs Investors Llc sold 29,620 shares as Clorox Co Del (CLX)’s stock declined 1.16%. The Qs Investors Llc holds 45,138 shares with $5.95 million value, down from 74,758 last quarter. Clorox Co Del now has $18.18B valuation. The stock decreased 0.73% or $1.03 during the last trading session, reaching $140.96. About 1.10M shares traded or 26.34% up from the average. The Clorox Company (NYSE:CLX) has risen 1.68% since January 13, 2017 and is uptrending. It has underperformed by 15.02% the S&P500.

Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid formulations for the treatment of various medical conditions in Australia. The company has market cap of $69.65 million. The firm is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. It currently has negative earnings. It has strategic alliances with Knop Laboratories and CannPal Pty Ltd; and partnerships with AusCann Limited and Aunt Zelda’s Inc, as well as the Complutensé University, the Curtin University, and the Telethon Kids Institute.

Investors sentiment increased to 1.1 in Q3 2017. Its up 0.15, from 0.95 in 2017Q2. It increased, as 43 investors sold CLX shares while 223 reduced holdings. 57 funds opened positions while 236 raised stakes. 90.68 million shares or 2.85% more from 88.17 million shares in 2017Q2 were reported. Credit Agricole S A reported 285,691 shares. Mercer Advisers Incorporated holds 646 shares. Corbyn Inc Md holds 2,000 shares. Bokf Na reported 94,726 shares. Td Asset Mgmt reported 427,415 shares. Eastern Natl Bank has 1,725 shares. Bancorp Of Hawaii, a Hawaii-based fund reported 6,998 shares. Central National Bank & Trust & Tru reported 0.21% in The Clorox Company (NYSE:CLX). Lincoln Natl Corporation stated it has 0.02% in The Clorox Company (NYSE:CLX). Perigon Wealth Management Lc holds 0.15% or 3,512 shares in its portfolio. Proshare Advsr Ltd Com reported 464,980 shares stake. California-based Main Street Research Ltd has invested 0.23% in The Clorox Company (NYSE:CLX). Seaward Lp holds 0.01% of its portfolio in The Clorox Company (NYSE:CLX) for 1,989 shares. Hanson Mcclain Incorporated invested in 0.02% or 1,724 shares. Fdx Incorporated reported 0.06% stake.

Qs Investors Llc increased Ltc Pptys Inc (NYSE:LTC) stake by 8,374 shares to 21,981 valued at $1.03 million in 2017Q3. It also upped Kla (NASDAQ:KLAC) stake by 3,015 shares and now owns 6,295 shares. Assured Guaranty Ltd (NYSE:AGO) was raised too.

Analysts await The Clorox Company (NYSE:CLX) to report earnings on February, 2. They expect $1.22 earnings per share, down 2.40% or $0.03 from last year’s $1.25 per share. CLX’s profit will be $157.30 million for 28.89 P/E if the $1.22 EPS becomes a reality. After $1.46 actual earnings per share reported by The Clorox Company for the previous quarter, Wall Street now forecasts -16.44% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News